Abstract
Deep venous thrombosis and its consequences remain a significant clinical challenge despite advances in the current healthcare system. The use of thrombolytic therapy has played an important role in the management of both arterial and venous thrombotic conditions. In this article, relevant clinical evidence and rationale in support of thrombolytic therapy in ileofemoral deep venous thrombosis are discussed.
MeSH terms
-
Angioplasty
-
Anticoagulants / therapeutic use
-
Chronic Disease
-
Femoral Vein
-
Fibrinolytic Agents / therapeutic use
-
Humans
-
Iliac Vein
-
Prosthesis Implantation
-
Stents
-
Streptokinase / therapeutic use
-
Thrombectomy
-
Thrombolytic Therapy / methods*
-
Tissue Plasminogen Activator / therapeutic use
-
Urokinase-Type Plasminogen Activator / therapeutic use
-
Venous Insufficiency / etiology
-
Venous Insufficiency / prevention & control*
-
Venous Thrombosis / complications
-
Venous Thrombosis / drug therapy*
-
Venous Thrombosis / therapy
Substances
-
Anticoagulants
-
Fibrinolytic Agents
-
Streptokinase
-
Tissue Plasminogen Activator
-
Urokinase-Type Plasminogen Activator